Zheng Tianying, Wang Aijun, Hu Dongyan, Wang Yonggang
Cancer Center, Qilu Hospital, Shandong University, Jinan, Shandong 250012, P.R. China.
Exp Ther Med. 2017 Sep;14(3):2162-2170. doi: 10.3892/etm.2017.4777. Epub 2017 Jul 11.
The present study indicated the successful construction of a silica nanoparticle (SLN)-based drug delivery system (DDS) for the tumor-targeted co-delivery of two anti-angiogenic drugs, candesartan (CD) and trastuzumab (Tra), for ovarian cancer therapy via different anti-angiogenic mechanisms using hyaluronic acid (HA)/Tra/CD/SLNs. and anti-angiogenic assays indicated that CD and Tra exert beneficial functions on suppressing cancer angiogenesis, and exhibited significantly enhanced effects compared with the angiotensin stimulated group (P<0.01). CD and Tra co-delivery also significantly increased the anti-angiogenic effect compared with applying either drug alone (P<0.01). Furthermore, HA on the surface of the DDS was demonstrated to reduce the cytotoxicity of the DDS and also endowed the particles with an advanced tumor-homing property and . The present results revealed that HA/Tra/CD/SLNs may be a preferable formulation for anti-angiogenic ovarian cancer therapy.
本研究表明，成功构建了一种基于二氧化硅纳米颗粒（SLN）的药物递送系统（DDS），用于通过透明质酸（HA）/曲妥珠单抗（Tra）/坎地沙坦（CD）/SLNs以不同的抗血管生成机制对两种抗血管生成药物CD和Tra进行肿瘤靶向共递送，用于卵巢癌治疗。抗血管生成分析表明，CD和Tra对抑制癌症血管生成具有有益作用，与血管紧张素刺激组相比，其作用显著增强（P<0.01）。与单独使用任何一种药物相比，CD和Tra共递送也显著增强了抗血管生成作用（P<0.01）。此外，DDS表面的HA被证明可降低DDS的细胞毒性，并赋予颗粒先进的肿瘤归巢特性。目前的结果表明，HA/Tra/CD/SLNs可能是抗血管生成卵巢癌治疗的优选制剂。
